Clinical characteristics of patients in Peg-IFN and NUC cohorts
| Peg-IFN cohort (N=231) | NUC cohort (N=560) | p Value | |
|---|---|---|---|
| Male gender (%) | 184 (79.7) | 455 (81.3) | 0.604 |
| Age, years | 29.1±6.8 | 30.1±8.9 | 0.084 |
| HBV genotype (%) | 0.557 | ||
| B | 81 (35.1) | 217 (38.8) | |
| C | 148 (64.1) | 340 (60.7) | |
| Others | 2 (0.9) | 3 (0.5) | |
| Baseline ALT level, IU/mL | 200.0±172.7 | 192.4±172.7 | 0.005 |
| ≥2×ULN (%) | 189 (81.8) | 448 (80.0) | 0.557 |
| Baseline HBV DNA level, log10 copies/mL | 8.4±1.3 | 8.5±1.1 | 0.646 |
| ≥ 9 log10 copies/mL (%) | 87 (37.7) | 218 (39.4) | 0.739 |
| Baseline HBsAg level, log10 IU/mL | 4.0±0.7 | 4.2±0.7 | <0.001 |
| Baseline HBeAg level, log10 PEIU/mL | 2.4±1.0 | 2.6±0.9 | 0.005 |
| Baseline anti-HBc level, log10 IU/mL | 4.3±0.5 | 4.2±0.5 | 0.038 |
| HBeAg seroconversion at end of study (%) | 99 (42.9) | 137 (24.5) | <0.001 |
ALT, alanine aminotransferase; anti-HBc, hepatitis B core antibody; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; NUC, nucleos(t)ide analogue; Peg-IFN, peginterferon; ULN, upper limit of normal.